Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Sinusitis Overview | 7 | 1 |
| Therapeutics Development | 8 | 1 |
| Pipeline Products for Sinusitis Overview | 8 | 1 |
| Sinusitis Therapeutics under Development by Companies | 9 | 2 |
| Sinusitis Pipeline Products Glance | 11 | 3 |
| Late Stage Products | 11 | 1 |
| Clinical Stage Products | 12 | 1 |
| Early Stage Products | 13 | 1 |
| Sinusitis Products under Development by Companies | 14 | 1 |
| Sinusitis Companies Involved in Therapeutics Development | 15 | 12 |
| AmpliPhi Biosciences Corporation | 15 | 1 |
| F. Hoffmann-La Roche Ltd. | 16 | 1 |
| Knopp Biosciences LLC | 17 | 1 |
| Kyorin Pharmaceutical Co., Ltd. | 18 | 1 |
| Kyowa Hakko Kirin Co., Ltd. | 19 | 1 |
| Merck &Co., Inc. | 20 | 1 |
| Oticpharma Ltd | 21 | 1 |
| Paratek Pharmaceuticals, Inc. | 22 | 1 |
| Pfizer Inc. | 23 | 1 |
| Quorum Innovations LLC | 24 | 1 |
| Regeneron Pharmaceuticals Inc | 25 | 1 |
| Therabron Therapeutics, Inc. | 26 | 1 |
| Sinusitis Therapeutics Assessment | 27 | 9 |
| Assessment by Monotherapy Products | 27 | 1 |
| Assessment by Target | 28 | 2 |
| Assessment by Mechanism of Action | 30 | 2 |
| Assessment by Route of Administration | 32 | 2 |
| Assessment by Molecule Type | 34 | 2 |
| Drug Profiles | 36 | 50 |
| ABSA-01 Drug Profile | 36 | 2 |
| benralizumab Drug Profile | 38 | 4 |
| CG-201 Drug Profile | 42 | 1 |
| dexpramipexole dihydrochloride Drug Profile | 43 | 3 |
| dupilumab Drug Profile | 46 | 6 |
| fluticasone propionate Drug Profile | 52 | 2 |
| KRPAM-1977X Drug Profile | 54 | 2 |
| omadacycline tosylate Drug Profile | 56 | 6 |
| omalizumab Drug Profile | 62 | 4 |
| P-008 Drug Profile | 66 | 1 |
| PCL-1404 Drug Profile | 67 | 1 |
| PF-06817024 Drug Profile | 68 | 1 |
| Qi-117 Drug Profile | 69 | 1 |
| RG-6149 Drug Profile | 70 | 1 |
| Small Molecule for Sinusitis Drug Profile | 71 | 1 |
| Small Molecule to Inhibit Soluble Epoxide Hydrolase for Sinusitis and Allergic Rhinitis Drug Profile | 72 | 1 |
| Small Molecules for Chronic Rhinosinusitis Drug Profile | 73 | 1 |
| solithromycin Drug Profile | 74 | 12 |
| Sinusitis Dormant Projects | 86 | 1 |
| Sinusitis Product Development Milestones | 87 | 5 |
| Featured News &Press Releases | 87 | 1 |
| Aug 09, 2016: AmpliPhi Biosciences Confirms Clinical Trial Progress | 87 | 1 |
| Aug 03, 2016: AmpliPhi Biosciences Completes Enrollment of Its Investigational Phage Therapy Trial Targeting Staphylococcus aureus | 87 | 1 |
| Apr 20, 2016: AmpliPhi Biosciences Provides Update on Phase I Trial: Phage Therapy Well Tolerated in First Cohort | 88 | 1 |
| Feb 03, 2016: Nasal polyps can be treated with medicine dupilumab | 88 | 1 |
| Feb 02, 2016: Sanofi and Regeneron Announce Publication of Positive Phase 2 Dupilumab Data in the Journal of the American Medical Association | 89 | 1 |
| Jan 20, 2016: AmpliPhi Biosciences Announces Dosing of First Patient in Phase 1 Clinical Trial of AB-SA01 | 89 | 1 |
| Nov 19, 2015: AmpliPhi Signs Clinical Trial Agreement with University of Adelaide to Conduct a Phase I Trial of Bacteriophage Therapy for Treating Staphylococcus aureus Infections | 90 | 1 |
| Jun 23, 2015: Jubilant Life Sciences receives ANDA approval for Levofloxacin Tablets | 90 | 1 |
| Sep 30, 2014: Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps | 91 | 1 |
| Appendix | 92 | 2 |
| Methodology | 92 | 1 |
| Coverage | 92 | 1 |
| Secondary Research | 92 | 1 |
| Primary Research | 92 | 1 |
| Expert Panel Validation | 92 | 1 |
| Contact Us | 92 | 1 |
| Disclaimer | 93 | 1 |